Please join the department in congratulating Dehua on the success of his efforts to commercialize key cyclic peptides for intracellular delivery of proteins. Chris Paschall of TCO states, “We believe it’s the largest deal in the history of Ohio State in terms of the upfront fee ($400K), and largest ever Series A financing round by an Ohio State spinout ($59M). The value of the deal speaks to the tremendous work that Dehua has done over the years.”
We greatly appreciate Dehua’s leadership in commercialization. His success is heartwarming and encouraging to others in the department who are moving technologies toward commercialization.
Dehua, we hope your innovations will help millions!